Directorate Change

RNS Number : 9006D
Syncona Limited
02 November 2020
 

Syncona Limited

Directorate Change

02 November 2020

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today announces Ellen Strahlman has retired as a Non-Executive Director with effect from 2 November 2020.

Melanie Gee, Chair of Syncona Limited, said: "The Board and management team would like to thank Ellen for her expert support and significant contribution to the Company and Syncona life science business since its inception in 2013. Ellen has been a non-executive Director with both Syncona Partners and Syncona Limited and her expertise in global product development and commercialization has been invaluable to draw on as the Company has progressed its strategy of founding and building global leaders in life science. We wish her well for the future."

  [ENDS]

Enquiries

Syncona Ltd

Annabel Clay  

Tel : +44 (0) 20 3981 7940

 

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com  

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFSMSMEESSEEF
UK 100

Latest directors dealings